INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

Impact · against what's priced in

PepGen faces significant downward pressure as a partial FDA clinical hold on its lead asset and a subsequent securities fraud investigation create regulatory and legal overhang. For ADMA and AWI, the news is less material as they are merely listed as other subjects of the law firm's investigations without specific new catalysts provided.

PEPG−0.80

No priced-in read yet